$RIGL

Rigel Pharmaceuticals presented data on GAVRETO (pralsetinib) at ESMO Congress 2026. Pooled trial analysis showed a 53% overall response rate in RET fusion-positive solid tumors. Additional data highlighted first-line outcomes and quality of life in RET fusion-positive NSCLC and thyroid cancer. The company aims to expand pralsetinib's use in RET fusion-positive cancers.

Telix announced US commercial availability of floretyrosine F 18, distributed by PharmaLogic, for differentiating glioma. Knight Therapeutics launched Tavalisse in Brazil for chronic immune thrombocytopenia, licensed from Rigel Pharmaceuticals.

Arvinas (ARVN) reported Q2 2026 revenue of $249.7M, up from $22.4M a year earlier, driven by FDA approval of VEPPANU and a licensing deal with Rigel. The FDA approved VEPPANU, the first PROTAC therapy, for advanced breast cancer. Arvinas licensed global rights to Rigel, generating $50M in milestone revenue and $62.5M in license revenue. The company expects three Phase 1 readouts in the next year. Cash reserves fell to $567.9M from $685.4M due to operational expenses.

Rigel Pharmaceuticals said its Veppanu (vepdegestrant) is now available by prescription in the US for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after progression on at least one endocrine therapy. Rigel calls it the first FDA-approved PROTAC, with a 200 mg daily dose and $29,400 per 30-day supply. The company cites improved progression-free survival vs fulvestrant in a pivotal trial.

Rigel Pharmaceuticals (Nasdaq: RIGL) said VEPPANU (vepdegestrant) is now available by prescription in the US for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after progression on at least one endocrine therapy line, per an FDA-authorized test. The drug is dosed 200 mg orally once daily and priced at $29,400 per 30-day supply.

Rigel Pharmaceuticals (RIGL) reported Q2 2026 revenue of $78.7 million, including $67.0 million net product sales and $11.7 million contract revenue. Net product sales rose 14% YoY. Full-year 2026 revenue guidance increased to $285 million to $295 million. Cash and investments were $95.3 million after a $70 million VEPPANU licensing payment to Arvinas and Pfizer.

Rigel Pharmaceuticals’ Q2 2026 earnings call said VEPPANU (vepdegestrant) in-licensing is a near-term growth driver, with mid-August 2026 commercial availability. Net product sales rose 14% YoY on TAVALISSE and REZLIDHIA. 2026 revenue guidance was raised to $285M-$295M, and Q2 net income was $17.3M. Rigel also discussed R289 milestones and QT prolongation warnings.

RIGEL PHARMACEUTICALS INC (RIGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rigel Reports Second Quarter 2026 Financial Results • Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 million • Expanded commercial p

RIGEL PHARMACEUTICALS INC (RIGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. rigl-20260625 0001034842 false 0001034842 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive VP and Chief Medical Officer, effective July 1, 2026, after she resigned from the board. She succeeds Lisa Rojkjaer, M.D. Rigel said R289 Phase 1b lower-risk MDS dose expansion enrollment is ongoing, targeting completion and Phase 2 dose selection in 2H 2026, with preliminary data by end-2026.